Jean‐Pierre Devogelaer

Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women

Henry G. Bone, David Hosking, Jean‐Pierre Devogelaer et al. · New England Journal of Medicine · 2004 · 1.3K citations · Full text

Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

Frédéric Houssiau, Jean‐Pierre Devogelaer, Jo Van Damme et al. · Arthritis & Rheumatism · 1988 · 850 citations

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

David M. Reid, Jean‐Pierre Devogelaer, Kenneth G. Saag et al. · The Lancet · 2009 · 525 citations · Full text

Bone Disease, Zoledronic Acid, Bone Health +5

Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial

Kenneth G. Saag, José Zanchetta, Jean‐Pierre Devogelaer et al. · Arthritis & Rheumatism · 2009 · 485 citations

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

Nick Bishop, Silvano Adami, S Faisal Ahmed et al. · The Lancet · 2013 · 196 citations

Bone Disease, Bone Health, Osteopathy +8